Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a Rights Issue and a Directed Share Issue. The Rights Issue and the Directed Share Issue have resulted in changes in the company’s number of shares and votes. Through the final registration of the Rights Issue, the number of shares has increased by 250,000 B-shares, and the number of votes has increased by 250,000. Through the final registration of the Directed Issue, the number of shares has increased by 6,666,666 B-shares, and the number of votes has increased by 6,666,666.
The total number of shares amounts to 185,029,787, of which 971,024 are A shares, and 184,058,763 are B shares. The total number of votes after the conversions amounts to 186,971,835. The share capital has increased by SEK 2,076,756.17 and now amounts to SEK 55,555,921.25.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on June 30, 2020.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] =>
[HtmlContact:protected] =>
[HtmlTitle:protected] => <h1><span style="line-height:120%;font-family:arial,helvetica,sans-serif"><span><span style="font-size:">Change in number of shares and votes in Episurf Medical</span></span></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a Rights Issue and a Directed Share Issue. The Rights Issue and the Directed Share Issue have resulted in changes in the company's number of shares and votes. Through the final registration of the Rights Issue, the number of shares has increased by 250,000 B-shares, and the number of votes has increased by 250,000. Through the final registration of the Directed Issue, the number of shares has increased by 6,666,666 B-shares, and the number of votes has increased by 6,666,666.
The total number of shares amounts to 185,029,787, of which 971,024 are A shares, and 184,058,763 are B shares. The total number of votes after the conversions amounts to 186,971,835. The share capital has increased by SEK 2,076,756.17 and now amounts to SEK 55,555,921.25.
For more information, please contact:
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on June 30, 2020.
[HtmlBody:protected] => <p><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt">Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a Rights Issue and a Directed Share Issue. The Rights Issue and the Directed Share Issue have resulted in changes in the company's number of shares and votes. Through the final registration of the Rights Issue, the number of shares has increased by 250,000 B-shares, and the number of votes has increased by 250,000. Through the final registration of the Directed Issue, the number of shares has increased by 6,666,666 B-shares, and the number of votes has increased by 6,666,666.</span></span><br>
<br>
<span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt">The total number of shares amounts to 185,029,787, of which 971,024 are A shares, and 184,058,763 are B shares. The total number of votes after the conversions amounts to 186,971,835. The share capital has increased by SEK 2,076,756.17 and now amounts to SEK 55,555,921.25.<br>
<br>
<strong>For more information, please contact:</strong><br>
Veronica Wallin, CFO, Episurf Medical<br>
Tel:+46 (0) 700 37 48 95<br>
<span style="font-size:10pt">Email: </span><a href="mailto:pal.ryfors@episurf.com">veronica.wallin@episurf.com</a><br>
<br>
<strong><span style="font-size:10pt">About Episurf Medical</span></strong></span></span></p>
<p><em><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt">Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</span></span></em></p>
<p><em><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt">This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, trough the agency of the contact person set out above, at 11:00 CEST on June 30, 2020.</span></span></em></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S8
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 075
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3144557/1271722.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Change in number of shares and votes in Episurf Medical
[Description:protected] => Change in number of shares and votes in Episurf Medical
[CreateDate:protected] => 2020-06-30T09:00:19.343Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3707033
[EncryptedId:protected] => 35759154BD32AA7A
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2020-06-30T09:00:00Z
[LastChangeDate:protected] => 2020-06-30T09:00:19.327Z
[Title:protected] => Change in number of shares and votes in Episurf Medical
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/change-in-number-of-shares-and-votes-in-episurf-medical,c3144557
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)